Company Data
Kiniksa Pharmaceuticals Ltd.
Ticker
KNSA
Current Price
$33.5 -0.59%
Market Cap
$2.5B
Price Target
Refer to Report
Volume
241.8K
52wk Range
$17.82 - $34.5455
Overview
Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404.